Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Dr. Stavroula Rakitzi
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06993662CT.gov The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective. | — | Active Not Recruiting | — | — | — |
NCT06011460CT.gov Observation of Clozapine Treatment Safety in Bipolar Disorder. | — | Enrolling By Invitation | — | — | — |
NCT02893371CT.gov Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies | — | Terminated | — | — | — |
NCT02562287CT.gov Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder | — | Unknown | — | — | — |
NCT01498770CT.gov An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308) | — | Completed | — | — | — |
NCT00036582CT.gov Clozapine vs. Placebo in Treatment-Refractory Bipolar Disorder in Children and Adolescents | — | Completed | — | — | — |
NCT00029458CT.gov Clozapine for Treatment-Resistant Mania | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bipolar Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Clozapine (this asset) | Dr. Stavroula Rakitzi | Approved | BB · 68 |
| Asenapine | Dr. Stavroula Rakitzi | P4 | BBB |
| Lamotrigine | Johns Hopkins University | P4 | BBB |
| Lithium, Elemental | University of Aarhus | P4 | BBB |
| Paroxetine | Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital | P4 | BBB |
| Escitalopram | First Affiliated Hospital of Zhejiang University | P4 | BBB |
| Citalopram | University of Texas Southwestern Medical Center | P4 | BBB |
| Quetiapine | First Affiliated Hospital of Zhejiang University | P4 | BBB |
| Sertraline | University of Texas Southwestern Medical Center | P4 | BBB |
+42 more in the Bipolar Disorder cohort
Other indications for Clozapine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizophrenia | — | P4 | BB · 70 |
| Schizoaffective Disorder | — | P4 | BB · 70 |
| Cannabis Dependence | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Clozapine in Bipolar Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/clozapine-bipolar-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →